Imatinib Krka

Imatinib, the active ingredient in Imatinib Krka, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia, and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide.

Imatinib acts on malignant cells driven by specific tyrosine‑kinase pathways, providing targeted therapy for several hematologic and solid tumours.

- Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): induces remission by blocking BCR‑ABL signaling. - Gastrointestinal stromal tumor (GIST): inhibits c‑KIT and PDGFR to control tumor growth.

Imatinib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often transient. - Edema: peripheral swelling, especially of the ankles. - Fatigue: generalized tiredness. - Muscle cramps: intermittent skeletal muscle discomfort. - Rash: mild skin erythema.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury. - Cardiotoxicity: heart failure or reduced ejection fraction. - Severe neutropenia: marked decrease in neutrophil count. - Thrombocytopenia: low platelet levels leading to bleeding risk. - Pulmonary arterial hypertension: rare increase in pulmonary pressure. - Anaphylaxis: severe allergic reaction requiring immediate medical attention.

When prescribing Imatinib, clinicians should consider several safety measures and monitoring requirements.

- Baseline assessment: obtain complete blood count, liver function tests and renal function before initiating therapy. - Monitoring: repeat hematology and chemistry panels regularly to detect cytopenias or hepatic toxicity. - Drug interactions: review concomitant medications for CYP3A4 inhibitors or inducers. - Pregnancy and lactation: avoid use unless benefits outweigh potential risks; discuss with obstetric specialist. - Cardiovascular evaluation: assess for pre‑existing heart disease and monitor for signs of heart failure. - Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Imatinib interacts with several medicines that can alter its plasma concentration or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels and risk toxicity. - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): can lower imatinib exposure, reducing efficacy. - Antacids containing aluminum or magnesium: decrease absorption if taken simultaneously.

Moderate Interactions (Monitor Closely): - Acid‑suppressing agents (e.g., omeprazole, esomeprazole): may modestly reduce bioavailability. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Digoxin: potential increase in serum levels, monitor for toxicity.